Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.01 USD
+6.56 (0.75%)
Updated Jun 17, 2024 04:00 PM ET
Pre-Market: $888.50 +3.49 (0.39%) 8:22 AM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 885.01 +6.56(0.75%)
Will LLY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The Zacks Analyst Blog Highlights Berkshire Hathaway, Eli Lilly, PepsiCo, Hovnanian and IDT
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
Top Stock Reports for Berkshire Hathaway, Eli Lilly & PepsiCo
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
Other News for LLY
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Qiagen (QGEN) and Eli Lilly & Co (LLY)
Pfizer Stock: The Reversal Should Keep Going
Growing Demand for GLP-1 Puts Eli Lilly (NYSE:LLY) in Prime Position
Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity
Viking Therapeutics: A Contender In The Growing Obesity Treatment Landscape